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Abstract: Despite advances in surgical and chemotherapeutic treatment options, less than 
50% of patients with advanced-stage ovarian cancer survive five years after initial 
diagnosis. In this regard, novel treatment approaches are warranted utilizing molecularly 
targeted therapies directed against particular components of specific signaling pathways 
which are required for tumor development and progression. One molecular pathway of 
interest is the hedgehog (Hh) signaling pathway. Activation of the Hh pathway has been 
observed in several cancer types, including ovarian cancer. This review highlights the 
crucial role of Hh signaling in the development and progression of ovarian cancer and 
might lead to a better understanding of the Hh signaling in ovarian tumorigenesis, thus 
encouraging the investigation of novel targeted therapies. 
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1. Introduction 
Ovarian cancer is the fifth most lethal gynecologic malignancy in the Western world with an 
estimated 22,280 new cases and 15,500 deaths in 2012 in the United States alone [1]. Epithelial 
ovarian cancer accounts for over 90% of all ovarian malignancies and comprises five histological 
subtypes: serous, mucinous, endometrioid, undifferentiated and clear cell type. The remainder arises 
from germ cells or stromal cells [2]. Due to the lack of appropriate tumor markers and of clinically 
significant symptoms at early tumor stages, most patients are diagnosed at advanced stage III or IV [2]. 
The clinical behavior of this malignancy varies from an excellent prognosis and high probability of 
cure, to rapid progression and poor prognosis, reflecting variation in the tumors’ biological   
properties [2]. Despite good responses to the initial treatment, which involves surgery followed by 
chemotherapy, the five-year relative survival rate is only 44% [1]. The major unresolved clinical 
problems associated with ovarian cancer include malignant progression and rapid emergence of drug 
resistance against conventionally used chemotherapeutic agents. 
Currently, the etiology of ovarian cancer is still not fully understood. It is generally accepted that 
ovarian carcinoma arises from ovarian surface epithelium (OSE), a primitive mesothelium with both 
epithelial and mesenchymal characteristics [3]. The ovarian surface epithelium has the ability to 
differentiate diversely in response to different stimuli [3]. Ovarian cancer displays a unique 
characteristic: in contrast to other cancers, during carcinogenesis, it usually becomes more differentiated 
than the epithelium from which it originates and shows an increased E-cadherin expression upon 
progression [4]. 
The hedgehog (Hh) signaling pathway was initially discovered in 1980 through genetic analyses of 
segmentation of the Drosophila fruit fly [5]. In humans, the Hh pathway was identified to function as a 
key mediator of many fundamental processes during embryonic development. In more detail, the Hh 
pathway is involved in regulating differentiation and proliferation, including cell fate and number, in 
brains and spinal cords, and the pattern of limbs and internal organs, so that developing tissue reaches 
its correct size with the appropriate cell types and adequate degrees of vascularization and innervation. 
The Hh pathway even controls body heights as well as regulates aging and its associated chronic 
degenerative and inflammatory diseases [6–9]. Furthermore, Hh signaling promotes proliferation, 
regeneration and differentiation of somatic tissues in adults [6]. It also plays a pivotal role for 
maintaining the tissue stem cell population [10]. Inactivation of this pathway contributes to hereditary 
developmental defects such as holoprosencephaly, whereas hyperactivation of this pathway by 
mutations is found in human cancers, such as medulloblastoma, basal cell carcinoma (BCC) and 
extracutaneous cancers [11–14]. In this article, we give an overview regarding the signal transduction 
of the Hh pathway and discuss the role of Hh signaling in development and progression of cancer with 
special emphasis on ovarian cancer and its potential impact on future therapeutic strategies. 
2. Signal Transduction of the Hedgehog Pathway 
The general signaling mechanisms of the Hh pathway are conserved from insects to humans and  
are illustrated in Figure 1 [15]. Three Hh homologs with different spatial and temporal distribution 
patterns have been identified in humans in the early 1990s: Sonic hedgehog (Shh), Indian hedgehog Int. J. Mol. Sci. 2013, 14 1181 
 
(Ihh) and Desert hedgehog (Dhh) [16–18]. Following translation, the Hh protein precursor enters the 
secretory pathway and undergoes autoprocessing and lipid modifications to release its N-terminal 
fragment (HhN), which is bound to a cholesterol moiety at the C-terminal end [19–21]. Several 
molecules are involved in the reception of Hh ligands, with Patched (PTC, one PTC in fly and two 
PTC in vertebrates—PTCH1 and PTCH2) representing the major receptor [22]. Hh binding to the  
PTC on the target cell initiates the Hh signaling cascade [23]. The Hh-interacting protein (HIP) 
competes with PTC to bind Hh, leading to a negative regulation of Hh signaling [24]. In the absence of 
the Hh ligand, PTC represses the activity of Smoothened (SMO), the seven transmembrane   
domain-containing protein, which serves as the key signal transducer [25]. However, it is still not clear 
how the binding of Hh proteins results in the pathway activation. One hypothesis is that PTC inhibits 
the function of SMO in the absence of Hh by transporting small endogenous molecules specifically 
targeted to SMO, such as PI4P, lipoproteins, and pro-vitamin D3 [26–28]. Binding of Hh to PTC 
shuttles PTC out of the cilium, so that it is no longer able to inhibit SMO, resulting in downstream 
inhibition of molecules by SMO signaling. There are two important events during mammalian SMO 
signaling. First, the SMO protein passes through conformational changes to favor intermolecular 
interaction of SMO [29]. Second, translocation of mammalian SMO to cilia plays an important role 
during Hh signaling. The function of primary cilium is regulated by large protein complexes involved 
in intraflagellar transport (IFT), which functions in anterograde and retrograde movement of cargo 
within the primary cilia [30]. Several Hh components, including SMO and Gli molecules, are also 
present at the primary cilium, highlighting the impact of cilium in Hh signaling [31,32]. As a 
transcription factor, Gli protein can regulate target gene expression by association with specific 
consensus sequences located in the promoter region of the target gene [33]. It has been reported that 
SMO mutants lacking a ciliary translocation signal fail to mediate Hh signaling [34]. However,   
recent data indicate the translocation of SMO to cilium as not being sufficient to activate Hh   
signaling [32,35]. Using tissue-specific gene knockout, recent studies demonstrate dual roles of cilium 
in Hh signaling-mediated carcinogenesis in a mouse model by knocking out the cilium component 
Kifa3 [32,36]. Whereas Kifa3 is required for activated SMO-mediated tumor formation, deletion of 
Kifa3 catalyzes Gli2-mediated carcinogenesis. In Drosophila, several molecules, including COS2 and 
Fused (Fu), have been identified downstream to SMO signaling, but it has to be elucidated how their 
vertebrate homologs function in Hh signaling. Analysis of the function of vertebrate homologs of 
COS2, KIF7 and the closely related KIF27 in cultured mammalian cells has led to the conclusion that 
neither protein has a role in Hh signaling [37]. However, recent in vivo studies suggest a role for Kif7 
in coordinating Hh signal transduction in mice, yet no direct interaction between SMO and KIF7 has 
been detected, thus indicating that the function of COS2 in vertebrates is replaced by other   
molecules [38]. In Fu null mice, no changes of Hh signaling have been observed, indicating that Fu is 
not critical for Hh signaling during embryonic development of vertebrates [39]. In mammalian cells, 
several novel cytoplasmic regulators of Hh signaling have been discovered, including Rab23 and 
tectonic [40,41]. Both are negative regulators of Hh signaling situated downstream of SMO. Rab23 is 
localized in the nucleus as well as in the cytoplasm, implying other yet unknown functions apart from 
membrane trafficking [42]. Recent data suggest that Suppressor of Fused (Su(Fu)) operates as a tumor 
suppressor gene in mammalian cells. Su(Fu) was identified in Drosophila by its ability to suppress 
active fused mutations, but it is not required for the activity of the pathway. Su(Fu) null mouse   Int. J. Mol. Sci. 2013, 14 1182 
 
mutants are inefficient in repressing the pathway and have some phenotypes similar to PTCH1   
inactivation [43]. PTCH1
+/− mice develop medulloblastoma, rhabdomyosarcoma and basal cell 
carcinoma following irradiation, whereas Su(Fu)
+/− mice predominantly develop basaloid epidermal 
proliferations [44–46]. Loss of Su(Fu) results in the activation of Hh signaling, indicating a central role 
of Su(Fu) in the pathway repression [43]. At the molecular level, Su(Fu) was found to associate 
directly with Gli function and is essential for Gli3 processing [47,48]. Finally, Hh signaling activates 
downstream Gli transcription factors, known to regulate target gene expression by binding to a 
consensus binding site in the promoter of the target gene region [33,49,50]. Several regulatory 
feedback loops are found in the Hh pathway, maintaining the level of Hh signaling in cells. PTC and 
HIP provide negative feedback mechanisms. In contrast, Gli1 and GAS1 form positive regulatory 
loops. Alterations of these loops result in abnormal signaling of the Hh pathway, such as loss of 
PTCH1 in BCC.  
Figure 1. Overview of the Hedgehog signaling pathway: a simplified model for Hh 
signaling in mammalian cells. SMO is the key transducer of the Hh pathway. (a) In the 
absence of the Hh ligands, the putative Hh receptor PTC is localized in the cilium and 
inhibits SMO signaling. Gli molecules are processed with the help of Su(Fu)/KIF7 
molecules into repressor forms, which deactivate the Hh signaling pathway. (b) In the 
presence of Hh, PTC is displaced out of the cilium and unable to inhibit SMO. Hh 
reception facilitates conformational changes in SMO, promoting Gli activation (GliA) and 
stimulation of Hh target gene expression. Su(Fu) and KIF7 can inhibit this process.  
 
3. Activation of the Hedgehog Pathway in Human Cancer  
Significant progress in gaining knowledge about Hh signaling in human cancers was achieved   
by the discovery that mutations of the human homolog of the Drosophila patched gene (PTCH1)  
are associated with a rare hereditary form of BCC (basal cell nevus syndrome, also called Gorlin 
syndrome) [51,52]. Gorlin syndrome is a rare autosomal genetic disorder with two distinct sets of 
phenotypes: a high risk of BCC and a predisposition to develop medulloblastoma and developmental 
defects such as bifid ribs and ectopic calcification. The role of PTCH1 has been further demonstrated 
in knockout mice: mice heterozygous for PTCH1 null mutation showed essential features observed in Int. J. Mol. Sci. 2013, 14 1183 
 
patients with Gorlin syndrome, such as malignant tumors (medulloblastomas, rhabdomyosarcomas, 
basal cell carcinomas) and developmental defects, such as spina bifida occulta [45,46,53]. BCC, one of 
the most common human cancers, regularly shows abnormalities of the Hh pathway arising from 
mutations in PTCH1 (50%), SMO (10%) and other genes, including Su(Fu) [54,55]. About one third 
of medulloblastomas show activated Hh signaling, and mutations influencing the signaling cascade 
could be commonly detected within the PTCH1 gene. Increasing evidence supports the notion that the 
activation of Hh signaling plays an important pathophysiolocial role in many types of human cancer. It 
is postulated that over 30% of human cancers are presented with activated Hh signaling, including 
brain tumors, melanomas, leukemias, lymphomas, gastrointestinal, kidney, bladder, pancreatic, liver, 
prostate, lung, ovarian and breast cancers [56]. In those cancers, gene mutation is not primarily 
responsible for activated Hh signaling, but rather caused by ligand-dependent mechanisms or   
non-canonical Hh signaling activation [57,58].  
4. The Role of Hedgehog Signaling in Cancer Initiation and Progression  
Recent data indicate that Hh signaling is involved in different stages of carcinogenesis. In Barrett’s 
esophagus, an early precursor of esophageal adenocarcinomas, the expression of Shh and Ihh is 
increased in the epithelium, which is associated with stromal expression of the Hh target genes PTCH1 
and BMP4 [59]. These results suggest that Hh signaling plays a significant role in the initiation of 
esophageal adenocarcinomas. Furthermore, activation of this pathway was observed in pancreatic 
intraepithelial neoplasia (PanIN) lesions as well in metastases of pancreatic cancer, suggesting   
that Hh signaling is also important for pancreatic cancer [60]. However, transgenic mice with 
pancreatic-specific expression of Shh or Gli2 develop undifferentiated pancreatic tumors which 
substantially differ from pancreatic ductal adenocarcinomas (PDAC), indicating that exclusive 
activation of Hh signaling is not sufficient to trigger PDAC development [61]. In gastric and prostate 
cancers, the activation of Hh signaling is associated with cancer progression [62–64]. In line with these 
observations, the inhibition of Hh signaling in prostate and gastric cancer cells reduces tumor cell 
invasiveness [63,65,66]. Increasing evidence also suggests that Hh signaling plays an important role in 
the development and progression of glioma, breast cancer, ovarian cancer, leukemia, and B-cell 
lymphoma [67–72]. The modes of Hh signaling in cancer development may vary from one tumor type 
to another. Several studies have indicated that in the absence of mutation in Hh pathway components, 
tumor cells synthesize and respond to Hh ligand in an autocrine-juxtacrine manner [57,65,73]. 
However, recent reports support an alternate model in which tumor-derived Shh or Ihh ligands trigger 
Hh signaling in the stromal environment in a paracrine manner [61,74]. It could be demonstrated that 
Hh pathway inhibition in pancreatic and colon carcinoma xenograft models blocks paracrine signaling 
between the tumor and its adjacent stroma [75]. A study in B-cell lymphomas proposes a different 
paracrine Hh signaling in which Shh is secreted by stromal cells to activate the Hh pathway in cancer 
cells [72,76]. It is noteworthy that correlation of Hh target gene expression with tumor specimens is 
not sufficient to clarify the role of Hh signaling in a specific cancer type. Establishing animal models 
using tissue specific activation of Hh signaling is crucial for understanding the role of Hh signaling in 
tumor progression. In an orthotopic model of pancreatic cancer, Yang et al. observed both paracrine 
and autocrine Hh signaling [77]. Increasing evidence indicates that Hh signaling is required for Int. J. Mol. Sci. 2013, 14 1184 
 
maintenance and function of cancer stem cell population. For example, leukemia stem cell 
maintenance and expansion was reported to be dependent on hedgehog signaling [78,79]. In the 
absence of SMO or treatment of cyclopamine, a specific inhibitor of the SMO co-receptor, the 
hematopoietic stem cell population is reduced. Based on cancer stem cell theory, it is assumed that  
Hh signaling activation may exert chemotherapy or radiotherapy resistance in cancer if this pathway 
has a major role in cancer stem cell functions [80]. Indeed, several studies have demonstrated that the 
activation of Hh signaling is associated with chemotherapy or radiotherapy resistance [81,82]. It was 
recently shown that the Hh signaling inhibitor IPI-926 enhances the delivery of the chemotherapeutical 
drug gemcitabine in a mouse model of pancreatic cancer [82]. Upon reviewing the literature on Hh 
signaling in human cancer, different results have been reported in different tumor types, and 
sometimes the results are contradictory to each other. These discrepancies are due to several reasons. 
First, it seems possible that the function of Hh signaling in human cancers may be context-dependent, 
occurring in some tissues or cell lines but not in others. For example, recent reports indicate that Hh 
signaling functions in maintaining cancer stem cell proliferation, but not in the proliferation of all 
cancer cells [78,79]. Second, the heterogeneity in tumor tissue is an essential factor in the analysis of 
Hh target gene expression by real-time PCR. For example, identification of activation of the Hh 
pathway in prostate cancer specimens can be obtained more frequently from transurethral resection of 
the prostate (TURP) specimens than from prostatectomy specimens [63]. Whereas the prostatectomy 
specimens contain only 5%–10% of tumor cells in the tissue, the TURP specimens generally have 
more than 70% of tumor cells. Therefore, the data from these two types of specimens may differ due to 
the percentage of cancer cells in each tissue. Third, different standards have been utilized to   
define Hh signaling activation. Some groups use elevated expression of Gli1 transcripts as the   
read-out of Hh signaling activation, whereas others examine the expression level of Hh target   
genes, such as Gli1, PTCH1, secreted frizzled-related protein 1 (sFRP1 ) and Hh-interacting protein 
(HIP) [64,65,68,83–85]. Similarly, some investigators apply exclusively immunohistochemistry to 
determine Hh signaling activation, whereas most studies use multiple approaches, including in situ 
hybridization, real-time PCR, and immunohistochemistry [71,86]. As the research in this area 
progresses, our knowledge about Hh-signaling activation in human cancer will also increase, 
accompanied by the development of appropriate methodological approaches [87]. 
5. Small Molecule Modulators of Hedgehog Signaling 
More than 50 compounds known to inhibit Hh signaling have been identified. Among these, five 
are used in clinical trials [88–97]. Three major targeting sites for Hh signaling have been determined: 
Hh molecules (Shh neutralizing antibodies, small molecule Robotnikinin), SMO protein (cyclopamine 
and its derivatives IPI-926, Cyc-T and synthetic compounds GDC-0449, Cur61414, XL-139, and 
LDE-225) and Gli inhibitors (HPI-1, HPI-2, GANT-56, and GANT-61). Hh signaling inhibitors can be 
divided into three groups: natural products (cyclopamine, its derivatives and other natural products), 
synthetic small molecules, and Hh signaling modulators. Table 1 lists the compound currently used in 
preclinical or phase I/II clinical trials, and Figure 2 gives an overview about the mode of action for 
some of these agents.  Int. J. Mol. Sci. 2013, 14 1185 
 
Table 1. Overview about currently tested Hedgehog signaling inhibitors. 
Inhibitor  In vitro/in vivo studies  References 
Cyclopamine  in vitro and in vivo studies  [98–101] 
KAAD cyclopamine  in vitro studies  [102] 
Jervine  in vitro studies  [103] 
Cyc T  in vitro and in vivo studies  [104] 
Cur 61414  Phase I clinical trial  [88] 
SANT 1,2,3,4  in vitro studies  [102] 
Compound 5  in vitro studies  [105] 
Compound Z  in vitro studies  [105] 
GANT-58, -61  in vitro and in vivo studies  [106] 
IPI 926  Phase I clinical trial and in vivo studies  [82,94,104,107] 
GDC-0449 (Vismodegib)  Phase I and II clinical trial  [89–93] 
BMS 833923 (XL139)  Phase I clinical trial  [95] 
LDE 225  Phase I clinical trial  [96] 
Vitamin D3  in vitro studies  [28] 
Robotnikinin  in vitro studies  [108] 
Figure 2. Overview about currently tested Hedgehog pathway inhibitors and their mode of action. 
 
5.1. Natural Products and Analogs (Cyclopamine, Its Derivatives, and Others) 
Cyclopamine is a plant-derived steroidal alkaloid which inhibits Hh signaling through direct 
binding to the transmembrane helices of SMO [97]. The discovery of specific, small molecule 
antagonists of SMO has established new options for the targeted therapy of human cancers associated 
with Hh signaling. The in vivo effect of cyclopamine on tumor shrinkage has been shown in several 
mouse models [98–100]. Cyclopamine derivatives with additional modifications aiming to increase 
acid stability and aqueous solubility are now available, such as IPI-926 and Cyc-T [94,104]. IPI-926 is Int. J. Mol. Sci. 2013, 14 1186 
 
now in use in clinical trials. In addition, several other synthetic compounds have been identified that 
directly inhibit SMO activity but with no structural similarity to cyclopamine [102,109]. 
5.2. Synthetic Hh Signaling Antagonists 
Several synthetic Hh inhibitors have been reported in the literature, most of them directed to   
SMO (e.g., GDC-0449) and other compounds targeting other Hh signaling components, including  
Shh and Gli.  
A clinical trial with vismodegib (GDC-0449) in a medulloblastoma patient resulted in a rapid 
reduction of tumor mass, but led to drug resistance due to SMO mutation [90,92]. Moreover, 
vismodegib was evaluated in a phase I, dose-escalation study of patients with refractory solid tumors. 
Activity was seen in patients with advanced BCC, medulloblastoma and other solid tumors [89–91]. A 
small-molecule inhibitor for Gli1 inhibited tumor cell proliferation in vitro and successfully blocked 
cell growth in an in vivo xenograft model using human prostate cancer cells harboring downstream 
activation of the Hh pathway [106]. Another small molecule called Robotnikinin was reported to bind 
Shh protein and to block Shh signaling in cell lines, human primary keratinocytes, and a synthetic 
model of human skin cancer [108]. Jervine was shown to block endogenous Shh signaling [103]. 
5.3. Hh Signaling Modulators 
Recent reports suggest that vitamin D3, whose secretion can be facilitated by PTCH1, inhibits SMO 
signaling through direct binding to SMO [28]. Promising data indicate that the effect of tazarotene, a 
retinoid with retinoic acid receptor (RAR) beta/gamma specificity against BCC carcinogenesis is 
sustained after its withdrawal [110]. Curcumin, a spice for cooking, has also been reported to block Hh 
signaling-mediated carcinogenesis. Several natural products, including genistein, EGCG, and 
resveratrol have also been reported to affect Hh signaling in a mouse model of prostate cancer [111]. 
6. Hedgehog Signaling and Ovarian Cancer 
Ovarian cancer is among the tumor entities where a tumorigenic activation of the Hh signaling 
pathway has been reported [68,112–115]. Aberrant activation of the Hh pathway is mediated through 
increased endogenous ligand-dependent expression of Hh or by ligand-independent mutations of 
PTCH, SMO and Su(Fu) in the pathway [116,117]. In a study by Liao et al., overexpression of PTCH 
and Gli1 protein in ovarian cancers correlated with poor survival of the patients. The subcellular 
localization of the Hh signal protein may also be important. While Gli1 expression was mainly 
observed in the cytoplasm of ovarian epithelial tumors, a high level of Gli1 expression in invasive 
cancer samples was associated with scattered nuclear Gli1 immunoreactivity [71]. Furthermore, 
significantly elevated expression of Shh mRNA was observed in ovarian cancers compared to normal 
tissues and benign ovarian tumors, and was specific for particular histological types.  
In addition, ectopic Gli1 overexpression in ovarian cancer cells increased cell proliferation,  
cell mobility, invasiveness and induced differentiation, identifying Gli1 expression as an   
independent prognostic marker [71]. Inhibition of the Hh pathway by treatment with   
3-keto-N-(aminoethyl-aminocaproyl-dihydrocinnamoyl)-cyclopamine, a specific inhibitor of the Hh Int. J. Mol. Sci. 2013, 14 1187 
 
pathway, induced cancer cell apoptosis, suppressed cell growth, mobility and invasiveness, and also 
induced cancer cell dedifferentiation [71]. According to Chen et al., the expression of Shh, Dhh, 
PTCH, SMO and Gli1 proteins was not observed in normal OSE, but was increased stepwise in 
benign, borderline and malignant neoplasms. In addition, immunoreactivity for Shh, Dhh, PTCH, 
SMO and Gli1 was strongly associated with cell proliferation assessed by Ki-67 [113]. Blocking the 
Hh signal using either cyclopamine or Gli1 siRNA resulted in remarkably decreased cell proliferation 
in ovarian carcinoma cells [113]. Treatment with cyclopamine induced not only G1 arrest but also 
apoptosis in ovarian carcinoma cells [113]. Among the Hh signal molecules, Dhh expression was 
correlated with poor prognosis of ovarian carcinoma patients [113]. As demonstrated by   
Ray  et al., the Hh pathway appears to be important in regulating growth of ovarian cancer   
spheroid-forming cells (SFCs) [112]. SFCs were treated with Hh agonists (Shh and Ihh) and the Hh 
inhibitor (cyclopamine) to detect changes in spheroid growth and survival. All four investigated 
ovarian cancer cell lines’ readily formed spheroids under non-adherent growth conditions, while the 
normal ovarian epithelial cell line failed to form SFCs. Moreover, compared to a control epithelial cell 
line, ovarian cancer cell lines demonstrated significant activation of the Hh pathway, determined by 
increased expression of intranuclear Gli1. Both Hh agonists showed significant increases in spheroid 
volume of at least 42-fold for Shh-treated cells, and 46-fold for Ihh-treated cells [112]. Regarding 
survival, SFCs were 30%–50% more resistant to cyclopamine than their corresponding monolayer 
cells [112]. Despite this resistance, inhibition of the Hh pathway with cyclopamine prevented further 
growth of SFCs. Taken together, the activation and inhibition of the Hh pathway showed significant 
association to enhanced growth and growth restriction, respectively [112]. 
Bhattacharya et al. investigated the effect of a specific Hh pathway blocker on clonal growth and 
proliferation of ovarian cancer cell, both in vitro and in vivo. Upregulation of the Hh pathway was 
observed in primary ovarian tumors and all of the human ovarian cancer cell lines tested. There, the 
authors demonstrated the Hh pathway to help maintaining the clonal growth of human ovarian 
carcinoma-derived cell lines. Moreover, the inhibition of Hh signaling by cyclopamine resulted in the 
inhibition of proliferation and clonal growth of all of the ovarian cancer cell lines in vitro and arrested 
the tumor growth in vivo. Furthermore, overexpression of PTCH1 inhibited the clonogenic   
capacity [68]. In a recent study, Yang et al. assessed Hh pathway activation in 34 ovarian epithelial 
tumor specimens by analyzing target gene expression by in situ hybridization, immunohistochemistry, 
and real-time PCR [114]. In contrast to previous reports, this group showed that the percentage of 
hedgehog signaling activation is low in ovarian cancer, suggesting that identification of tumors with 
activated hedgehog signaling activation will facilitate therapy with hedgehog signaling inhibitors. In 
addition, the authors found that even in the tumor with elevated expression of the hedgehog target 
genes Gli1 and PTCH1, expression of Shh is not correlated with Hh target gene expression, suggesting 
other mechanisms of hedgehog signaling activation in this particular cancer type. Moreover, the fact 
that hedgehog signaling activation was not associated with any particular subtypes of ovarian cancer 
implicates that the morphological classification of ovarian cancer may not reflect the molecular 
pathogenesis of this disease [114]. In line with this observation, Schmid et al. demonstrated that the 
expression of Hh pathway-related genes varied considerably among the investigated ovarian cancer 
tissue samples: more than half of the tumor samples showed Hh signaling or pathway activation, either 
by expression of transcription factors and Hh ligands, or by overexpression of Ihh/Shh and the Int. J. Mol. Sci. 2013, 14 1188 
 
PTCH1/PTCH2. In addition, gene expression heterogeneity between patient samples of the same 
histological type and grade was observed [115]. The conflicting results of the available studies might 
be due to the fact that different standards have been used to define Hh signaling activation in ovarian 
cancer, as already mentioned above, and that involvement of Hh signaling may occur only in specific 
tissues or cancer cell lines.  
7. Targeting Hedgehog Pathway in Ovarian Cancer  
In a recent study the potential role of Gli1 in resistance to anoikis—a cell death that occurs due to 
detachment of a cell from the extracellular matrix and hence a primary feature of a cell that undergoes 
metastasis—was demonstrated. Treatment of various ovarian cancer cells by different concentrations 
of diindolylmethane (DIM) reduced anoikis resistance in a concentration-dependent manner. 
Reduction in anoikis resistance is correlated with a decrease in the Gli1 expression. Shh treatment not 
only increased the expression of Gli1, but also blocked anoikis induced by DIM. To confirm the role 
of Gli1, cyclopamine was used, resulting in significantly reduced anoikis resistance in ovarian   
cancer cell lines associated with reduced expression of Gli1. Conversely, Shh treatment blocked   
cyclopamine-induced anoikis. Silencing Gli1 expression induced anoikis in the examined ovarian 
cancer cells. In vivo studies demonstrated that DIM- or cyclopamine-treated ovarian cancer cells under 
suspension culture conditions drastically lost their ability of tumor formation in vivo in mice [101]. 
McCann et al. investigated if inhibition of the Hh pathway could inhibit serous ovarian cancer growth. 
They used an in vivo preclinical model of serous ovarian cancer to characterize the antitumor activity 
of cyclopamine and IPI-926. Primary human serous ovarian tumor tissue was utilized to generate 
tumor xenografts in mice that were subsequently treated with cyclopamine or IPI-926 [107]. Both 
compounds showed significant antitumor activity as single agents [107]. When IPI-926 was used in 
combination with paclitaxel and carboplatin (T/C), no synergistic effect was observed. Maintaining 
treatment with IPI-926 after discontinuation of T/C continued to suppress tumor growth. Hh pathway 
activity was analyzed by RT-PCR to assess changes in Gli1 transcript levels. The results demonstrated 
that Gli1 expression in the stroma was specifically and significantly reduced within 24 hours of   
IPI-926 treatment, while expression of Gli1 in tumor cells was unaffected. However, prolonged   
(21 days) IPI-926 treatment led to significant decreases in both stromal and tumor Gli1 expression. 
These data suggest that prolonged inhibition of stromal Hh signaling could ultimately lead to 
decreased Hh signaling in tumor cells. The Gli1 mRNA expression data from the microdissected 
stroma of human serous ovarian cancer confirmed that the Hh pathway is active in human ovarian 
stroma, and demonstrated that elevated Gli1 mRNA levels are associated with shorter survival [107]. 
In a phase II, randomized, double-blind, placebo-controlled trial, vismodegib (GDC-0449) was 
tested to provide an estimate of efficacy in the setting of second or third complete remission in   
104 ovarian cancer patients. Although numerical improvements were observed, a clinically meaningful 
improvement in progression-free survival for vismodegib versus placebo maintenance could not be 
demonstrated, and Hedgehog ligand-expression frequency was lower than expected [93]. One possible 
explanation for this result is that Hh ligand overexpression is associated with chemotherapy resistance 
that could prevent patients from achieving complete remission and, therefore, of being eligible for this 
study. Alternatively, it is also conceivable that Hedgehog ligand overexpression is actually associated Int. J. Mol. Sci. 2013, 14 1189 
 
with a lower probability of relapse, leading to a lower prevalence of Hh-positive ovarian cancer in this 
study population [93]. This report underlines the importance of an appropriate patient selection 
strategy for further studies.  
8. Conclusions 
The etiology of ovarian cancer is still among the poorest understood of common human 
malignancies. Even though 70%–80% of affected women achieve a complete clinical response to first 
line treatment, including surgery, the majority develops recurrent disease. The linkage of Hh signaling 
activation to various human cancers, including ovarian cancer, and the discovery of novel   
Hh signaling inhibitors provides promising options for developing novel targeted therapeutic 
strategies. Despite these advances, there are multiple goals to address for the future. The optimized use 
of Hh signaling antagonists accompanied by rational patient selection will increase the potential of Hh 
inhibitors as alternative molecularly targeted anticancer drugs. Well-designed clinical trials are 
necessary to evaluate the real potential of such pathway inhibitors. A rational patient selection will be 
based on tumor tissue-based expression or mutational testing with regard to the investigated   
Hh signaling inhibitor. Overexpression or pathway activation by gene mutations of members of the Hh 
signaling cascade might predict the efficacy of Hh signaling inhibitors and should therefore be tested 
and included as a translational research approach in each clinical trial. These steps could lead to the 
identification of predictive biomarkers to better identify patient subpopulations that will benefit from 
an Hh-targeted therapy. A better understanding of the underlying mechanisms of resistance is also 
urgently needed. Achieving these goals will be of paramount importance for designing targeted 
therapeutic strategies for ovarian cancer. 
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